Number of the records: 1
Mitochondrially Targeted alpha-Tocopheryl Succinate Is Antiangiogenic: Potential Benefit Against Tumor Angiogenesis but Caution Against Wound Healing
- 1.
SYSNO ASEP 0369479 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Mitochondrially Targeted alpha-Tocopheryl Succinate Is Antiangiogenic: Potential Benefit Against Tumor Angiogenesis but Caution Against Wound Healing Author(s) Rohlena, Jakub (BTO-N) RID, ORCID
Dong, L.-F. (AU)
Klučková, Katarína (BTO-N) RID
Zobalová, Renata (BTO-N) RID
Goodwin, J. (AU)
Tilly, D. (AU)
Štursa, Jan (UOCHB-X)
Pecinová, Alena (FGU-C) RID, ORCID, SAI
Philimonenko, Anatoly (UMG-J)
Hozák, Pavel (UMG-J) RID, ORCID
Banerjee, J. (US)
Ledvina, Miroslav (UOCHB-X) RID
Sen, Ch.K. (US)
Houštěk, Josef (FGU-C) RID, ORCID
Coster, M.J. (AU)
Neužil, Jiří (BTO-N) RIDSource Title Antioxidants & Redox Signaling. - : Mary Ann Liebert - ISSN 1523-0864
Roč. 15, č. 12 (2011), s. 2923-2935Number of pages 13 s. Language eng - English Country US - United States Keywords Analogs of alpha-tocopheryl succinate ; MitoVES ; inhibition of angiogenesis Subject RIV EB - Genetics ; Molecular Biology R&D Projects 1M0520 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) KAN200520703 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) GA305/07/1008 GA ČR - Czech Science Foundation (CSF) GAP301/10/1937 GA ČR - Czech Science Foundation (CSF) GA204/08/0811 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50520701 - BTO-N (2007-2013) AV0Z50110509 - FGU-C (2005-2011) AV0Z4055905 - UOCHB-X AV0Z5052915 - UMG-J UT WOS 000296588900002 DOI 10.1089/ars.2011.4192 Annotation A plausible strategy to reduce tumor progress is the inhibition of angiogenesis. We tested the antiangiogenic potential of a mitochondrially targeted analog of alpha-tocopheryl succinate (MitoVES) with high propensity to induce apoptosis. MitoVES was found to efficiently kill proliferating endothelial cells (ECs) but not contact-arrested ECs or ECs deficient in mitochondrial DNA. It suppressed angiogenesis in vitro by inducing ROS accumulation in proliferating/angiogenic ECs. Resistance of arrested ECs was ascribed to the lower mitochondrial inner transmembrane potential compared with the proliferating ECs, thus resulting in the lower level of mitochondrial uptake of MitoVES. Shorter-chain homologs of MitoVES were less efficient in angiogenesis inhibition. MitoVES was found to suppress HER2-positive breast carcinomas in a transgenic mouse as well as inhibit tumor angiogenesis. The antiangiogenic efficacy of MitoVES was corroborated by its inhibitory activity on wound healing in vivo. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2012
Number of the records: 1